Wednesday, March 12, 2025 3/12/2025

Understanding mechanisms and implications of Acinetobacter carbapenem resistance via whole genome sequencing and associated patient outcomes

Award Number: R03HS027667
ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY
OPDIV: AHRQ
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

SUMMARY/ABSTRACT Carbapenemase producing Acinetobacter infections mostly occur in critically ill hospitalized patients, immunocompromised patients and patients administered with carbapenems. This poses an important problem as carbapenems are the drugs of choice for treatment of Acinetobacter infections. Therefore, studies understanding antibiotic resistance mechanisms in Acinetobacter is of paramount importance. With high resolution data available from whole genome sequencing (WGS) and our ability to perform both sequencing and bioinformatic analysis in house, we aim to identify the Acinetobacter resistance genes present in both the chromosomal and plasmid DNA. Our long-term goal is to understand the emergence and spread of resistance genes of Acinetobacter and how it contributes to patient outcomes. We hypothesize that patients with Acinetobacter infections can have different patient outcomes based on the resistance genes they harbor. The objective of this pilot research is to identify the different resistance genes or its variants in Acinetobacter that contribute to adverse patient outcomes such as prolonged infection leading to increased duration of stay and mortality. The central hypothesis will be addressed by the following specific aims 1) Identify all chromosomal or plasmid derived antibiotic-resistance genes harbored by the carbapenem-resistant Acinetobacter baumannii (CRAb) isolates via whole genome sequencing (WGS) and computational analysis 2) Determine if any resistance genes or variants of these genes in the CRAb isolates act as a predictor of adverse clinical outcomes. In addition to the above-mentioned goals, this study will provide a unique opportunity to understand the epidemiology of Acinetobacter infections using whole genome multilocus sequence typing MLST (wgMLST) in a clinical setting. This integrated approach with whole genome DNA sequencing, plasmid sequencing, epidemiologic surveillance and patient outcome data in a non-outbreak situation will allow us to comprehensively evaluate the high-risk Acinetobacter clades and prioritize treatment options for those patients. The findings from the proposed research will advance our understanding of the epidemiology and implications of resistance mechanisms that contribute to adverse patient outcomes to improve resource prioritization in healthcare facilities.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	CENTRAL TEXAS VETERANS RESEARCH FOUNDATION	RESEARCH OFFICE (151N) 1901 S 1ST ST	TEMPLE	TX	76504	BELL	USA	Research on Healthcare Costs, Quality and Outcomes	000	2	11/30/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $42,395 )
2021	2021	CENTRAL TEXAS VETERANS RESEARCH FOUNDATION	RESEARCH OFFICE (151N) 1901 S 1ST ST	TEMPLE	TX	76504	BELL	USA	Research on Healthcare Costs, Quality and Outcomes	001	2	7/27/2021	NON-COMPETING CONTINUATION	$42,395
2021	2020	CENTRAL TEXAS VETERANS RESEARCH FOUNDATION	RESEARCH OFFICE (151N) 1901 S 1ST ST	TEMPLE	TX	76504	BELL	USA	Research on Healthcare Costs, Quality and Outcomes	000	1	7/27/2021	NEW	$0
														Subtotal = $42,395

Issue Date FY: 2020 ( Subtotal = $42,395 )
2020	2020	CENTRAL TEXAS VETERANS RESEARCH FOUNDATION	RESEARCH OFFICE (151N) 1901 S 1ST ST	TEMPLE	TX	76504	BELL	USA	Research on Healthcare Costs, Quality and Outcomes	000	1	7/30/2020	NEW	$42,395
														Subtotal = $42,395

Grand Total All Awards = $84,790

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Understanding mechanisms and implications of Acinetobacter carbapenem resistance via whole genome sequencing and associated patient outcomes

Award Number: R03HS027667

ORGANIZATION: AGENCY FOR HEALTH CARE RESEARCH AND QUALITY

OPDIV: AHRQ

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer